LLY Jan 2025 670.000 call
| Previous close | 125.55 |
| Open | 125.55 |
| Bid | 0.00 |
| Ask | 0.00 |
| Strike | 670.00 |
| Expiry date | 2025-01-17 |
| Day's range | 125.55 - 125.55 |
| Contract range | N/A |
| Volume | |
| Open interest | 141 |
BloombergInvestors Pile Into Amgen in Search of Next Obesity Drug Payout
(Bloomberg) -- Investors who may have missed out on the blistering rally in Eli Lilly & Co. and Novo Nordisk A/S are once again taking a chance with Amgen Inc.Most Read from BloombergTruce Talks Drag as Hamas Hits Israel Crossing in Deadly AttackBuffett Praises Apple After Trimming It, Drops Paramount StakeFrance’s Macron Calls for Reset of Economic Ties With ChinaTreasury Rally Risks Running Into a $125 Billion Brick WallXi Begins Europe Tour in Paris as Macron Seeks to Reset TiesThe shares sur
Barrons.comAmazon Stock Is on a Roll. Here’s Why It’s on This Firm’s ‘Best Ideas List.’
Amazon reported strong first-quarter results, with revenue and operating income ahead of expectations. The company delivered operating income of $15.3 billion, above consensus of $11.3 billion, while reporting better-than-expected growth in both Amazon Web Services (+17.2% year over year versus Street +15%) and advertising (+24.3% Y/Y versus Street +23.5%). Amazon has now reported operating income above the high end of its guidance range for five consecutive quarters, and the company has a number of drivers for further margin expansion in place, including continued cost efficiencies within its fulfillment network as well as the ongoing mix shift toward higher-margin AWS and advertising revenue.
Yahoo FinanceAmgen's peek at its GLP-1 drug trial results heightens competition in obesity market
Competition is heating up in the GLP-1 space as Amgen gets closer to the finish line with its candidate.
